Original Publication Date: >1 April, 2016
Publication / Source: CNS Oncology
Authors: Subramanian Venkatesan, Martine LM Lamfers, Clemens MF Dirven & Sieger Leenstra
Glioblastoma is the most deadly and frequently occurring primary malignant tumor of the central nervous system. Genomic studies have shown that mutated oncogenes and tumor suppressor genes in glioblastoma mainly occur in three pathways: the RTK/Ras/PI3K signaling, the p53 and the Rb pathways. In this review, we summarize the modulatory effects of genetic aberrations in these three pathways to drugs targeting these specific pathways.